Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal

MT Newswires Live

Jul 25

Lisata Therapeutics (LSTA) shares were down about 17% in Friday afternoon trading after the company said it has terminated its previously announced proposed merger with Kuva Labs.

Lisata was informed that Kuva Labs failed to secure sufficient funding to fulfill the tender offer to acquire all of Lisata's outstanding shares, the company said in a Friday filing.

As a result of the termination, Lisata said it is entitled to a fee of $2 million and has the right to seek damages, but there is no assurance it will be able to obtain damages due to its limited funds for litigation and Kuva Labs' inability to satisfy its claims with its existing assets.

Price: 1.77, Change: -0.35, Percent Change: -16.51

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2654031755"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654031755\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654031755?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-25 02:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654031755","market":"sh","top_or_hot":-1,"title":"Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> (LSTA) shares were down about 17% in Friday afternoon trading after the company said it has terminated its previously announced proposed merger with Kuva Labs.</p><p>Lisata was informed that Kuva Labs failed to secure sufficient funding to fulfill the tender offer to acquire all of Lisata's outstanding shares, the company said in a Friday filing.</p><p>As a result of the termination, Lisata said it is entitled to a fee of $2 million and has the right to seek damages, but there is no assurance it will be able to obtain damages due to its limited funds for litigation and Kuva Labs' inability to satisfy its claims with its existing assets.</p><p>Price: 1.77, Change: -0.35, Percent Change: -16.51</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisata Therapeutics Shares Fall After Terminating Kuva Labs Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-25 02:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> (LSTA) shares were down about 17% in Friday afternoon trading after the company said it has terminated its previously announced proposed merger with Kuva Labs.</p><p>Lisata was informed that Kuva Labs failed to secure sufficient funding to fulfill the tender offer to acquire all of Lisata's outstanding shares, the company said in a Friday filing.</p><p>As a result of the termination, Lisata said it is entitled to a fee of $2 million and has the right to seek damages, but there is no assurance it will be able to obtain damages due to its limited funds for litigation and Kuva Labs' inability to satisfy its claims with its existing assets.</p><p>Price: 1.77, Change: -0.35, Percent Change: -16.51</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654031755","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654031755","pubTimestamp":1784919576,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lisata Therapeutics  shares were down about 17% in Friday afternoon trading after the company said it has terminated its previously announced proposed merger with Kuva Labs.Lisata was informed that Kuva Labs failed to secure sufficient funding to fulfill the tender offer to acquire all of Lisata's outstanding shares, the company said in a Friday filing.As a result of the termination, Lisata said it is entitled to a fee of $2 million and has the right to seek damages, but there is no assurance it will be able to obtain damages due to its limited funds for litigation and Kuva Labs' inability to satisfy its claims with its existing assets.Price: 1.77, Change: -0.35, Percent Change: -16.51","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技","LSTA":"LISATA THERAPEUTICS INC","BK4007":"制药"},"translate_title":"Lisata Therapeutics 终止 Kuva Labs 交易后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSTA":1,"LENZ":1.5},"content_text":"Lisata Therapeutics (LSTA) shares were down about 17% in Friday afternoon trading after the company said it has terminated its previously announced proposed merger with Kuva Labs.Lisata was informed that Kuva Labs failed to secure sufficient funding to fulfill the tender offer to acquire all of Lisata's outstanding shares, the company said in a Friday filing.As a result of the termination, Lisata said it is entitled to a fee of $2 million and has the right to seek damages, but there is no assurance it will be able to obtain damages due to its limited funds for litigation and Kuva Labs' inability to satisfy its claims with its existing assets.Price: 1.77, Change: -0.35, Percent Change: -16.51","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}